Teva Pharmaceuticals announced Feb. 17 that the U.S. Food and Drug Administration approved AUSTEDO XR (deutetrabenazine) extended-release tablets, a once-daily treatment for adults with tardive ...

(RTTNews) - Neurocrine Biosciences Inc. (NBIX) said that it will present new data from its movement disorder treatments for tardive dyskinesia or TD and Parkinson's disease at the International ...

Please provide your email address to receive an email when new articles are posted on . Teva Pharmaceuticals announced FDA approval of Austedo XR, a once-daily, extended-release formulation for adults ...

In 2024, several research and pharmacological advancements were made for tardive dyskinesia, a movement disorder caused by dopamine-blocking medications. Below are some of the highlights of the year.

Ingrezza (valbenazine) is a prescription drug that’s used to treat certain movement disorders. Ingrezza comes as a capsule that you swallow. Specifically, Ingrezza is used to treat these conditions in ...

Evoke Pharma, Inc. announced that an abstract comparing the incidence of tardive dyskinesia (TD) in patients undergoing continuous versus intermittent oral metoclopramide treatment has been accepted ...

TD often decreases patients’ quality of life through its effects on their physical, emotional, cognitive, and psychosocial well-being. An easy-to-use tool to assess the impact of TD might allow ...

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the initiation of a 3-year ...

SAN DIEGO, Aug. 29, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today presented findings from a data analysis of KINECT ®-4 demonstrating a comparable pattern of ...

People with movement disorders can have a difficult time doing day-to-day activities, which could impact their independence. This can affect how people see themselves and affect their social life.

The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes. Post-hoc analysis from ...

DUBLIN, Nov. 20, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2 clinical trial of ...